MAT Myth Busters
Friday, March 12, 2021
9:00 - 9:45am
The term opioid use disorder (OUD), is used for those suffering from the disease of addiction related to opioids (CDC, 2020b). Nearly 80% of Americans with OUD are not receiving appropriate care. While access to office-based addiction treatment has increased in recent years, distribution of medication-assisted treatment (MAT) has been slowing. (Saloner B, 2015) MAT is very effective and can save lives, however, physicians have misconceptions about the OUD patient population, MAT’s effectiveness, and how it works. Treatment for OUD usually centers on stabilizing the patient using MAT. A more recent understanding of addiction as a disease, using the medical model, has enabled us to apply evidence-based guidelines. Community physicians can prescribe buprenorphine, eliminating the need to visit a treatment center, and expanding access (National Institute for Drug Abuse, 2018). In order to achieve this, PCPs must be aware of the signs of opioid use disorder as well as intervention strategies when OUD is suspected. This includes recognizing their patients on chronic opioids for pain who may be developing a use disorder; this can be tricky and nuanced (Donroe, 2020). Barriers to OUD treatment in primary care include physician training and stigma (Korthuis, 2016) (Pew, 2020), which includes incorrect preconceived notions of how utilizing buprenorphine would affect a practice’s patient population. Managing MAT in primary care can be done with confidence and offer financial and personal.
At the end of this presentation, attendees will be able to:
- List common myths about MAT and patients with OUD, and explain why these myths are not barriers to providing MAT in your practice
- Recognize patients already within your practice who may have or be at risk for developing OUD
- Apply simple, focused, evidence-based interventions when OUD is suspected, including delineating among MAT choices
Lee Radosh, MD, FAAFP
Medical Director, Reading Hospital Center of Excellence for Opioid Use Disorder
Addiction Medicine Physician, Tower Health Medical Group
Dr. Radosh has disclosed that he has no financial conflict of interest relevant to this presentation.
During this presentation he will mention how buprenorphine can be used for chronic pain; some buprenorphine formulations are not FDA-approved for pain.
Thank you for attending ACPNJ's 2021 Virtual Scientific Meeting!
Thank you for participating in the 2021 ACPNJ Virtual Scientific Meeting. In order to complete this course and qualify for CME Credit, you must be logged into the website.
If the banner above shows "log in to enroll," please do so using the BLUE login button displayed on this page. All registered attendees are enrolled in each Scientific Meeting CME Course. (SEP Modules require separate registration).
Begin by completing the Session Evaluation. Make sure you click "Submit" at the end of the evaluation before continuing to the post-test.
Then complete the brief post-test. If you experience difficulty, please view the How to Claim CME menu item.
At the end of the live meeting, we will provide a link where you can complete your overall session evaluation and claim MOC credits, if you wish to do so.
If you have any difficulty or questions, please contact us by email by clicking here.
The following planners and reviewers have stated that they have no conflict of interest relative to this activity: Theresa J. Barrett, PhD, CMP, CAE; Mirela Feurdean, MD; Tamie Proscia-Lieto, MD; Jonathan Shammash, MD, FACP; Nayan Kothari, MD, Christine Bersani, Kathleen Cavallo; Herb Holland